<p>Sienna Pharmaceuticals is joining the small but growing biotech IPO renaissance this year as it goes for a $75 million offering. Currently, VC Arch Ventures owns the lion’s share of the company, with a 23.4% stake, with Partner Fund Management owning 9.5%.</p>